EICHOR
● Recruiting
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Condition: Sickle Cell Disease (SCD) · Sponsor: University Hospital, Toulouse
About this study
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.
This description comes directly from the study's public registry record.
Talk to the study team
Pierre COUGOUL, MD · 0531156265 · cougoul.pierre@iuct-oncopole.fr
Always discuss trial participation with your own doctor first.
Locations (1)
| CHU de Toulouse | Toulouse, France, France | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06887907